JPRN-UMIN000051645招募中Unknown
Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective study - Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective study
Graduate School of Medicine, Chiba University0 个研究点目标入组 80 人开始时间: 2023年7月19日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have expressed their refusal to participate in this study through an information disclosure document
研究者
相似试验
招募中
不适用
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.Hepatocellular carcinomaJPRN-UMIN000037054Yokohama City University Medical Center250
已完成
不适用
The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approvalHepatocellular carcinomaJPRN-UMIN000034333ational Hospital Organization Kyoto Medical Center500
进行中（未招募）
1 期
Treatment for patients whith graft-versus-host disease after bone marrow transplantation.Chronic graft-versus-host disease .MedDRA version: 14.1Level: LLTClassification code 10008907Term: Chronic GVH diseaseSystem Organ Class: 100000004870EUCTR2012-000770-36-BECHU-ULg5
进行中（未招募）
1 期
A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.EUCTR2015-001467-39-ITGETNE (GRUPO ESPAñOL DE TUMORES NEUROENDOCRINOS)110
已完成
不适用
Safety and efficacy of lenalidomide for patients with relapsed or refractory adult T cell leukemia/lymphoma post allogeneic hematopoietic stem cell transplantation, multi-institutional prospective observational trialAdult T-cell leukemia-lymphomaJPRN-UMIN000029635Kagoshima University33